Print 05 January 2017
Once the administrative process is complete, the U.S. Patent that issues from this application will provide intellectual property protection for methods of treating posterior ocular disorders by non-surgically administering axitinib to the suprachoroidal space of the eye. This patent represents one in a series of filings protecting the use of the suprachoroidal space as a location in the eye to dose drug that provides for higher bioavailability to target retinal and choroidal diseases, regardless of the method of administration.
In 2016, Clearside selected axitinib as the lead compound for its development program for the treatment of neovascular age-related macular degeneration (“wet AMD”) through suprachoroidal administration. In preclinical models, we observed that axitinib had a long drug half-life and high bioavailability in the tissues of the back of the eye. Axitinib targets all vascular endothelial growth factor receptors, in addition to other key receptors involved in angiogenesis.
“This is the seventh patent allowance in
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Clearside’s current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of Clearside’s product candidates. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Clearside’s reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in Clearside’s Quarterly Report on Form 10-Q for the quarter ended
Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.
21 March 2018
20 March 2018
20 March 2018